Ian Cassel
Long only, special situations, growth at reasonable price, research analyst

Should Exact Sciences Buy VolitionRx?

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

Colorectal cancer is the third most prevalent cancer in the US, with roughly one in 20 people diagnosed with the disease. While screening methods, such as the colonoscopy and fecal tests (FOBT/FIT) are used regularly, low patient compliance means that many people continue to be diagnosed later than ideal. However two companies, Exact Sciences (NASDAQ:EXAS) and VolitionRx (NYSEMKT:VNRX) are developing very different tests which each claim to pick up cancer earlier, using more sophisticated DNA-based analysis than is currently available.

Exact Sciences was...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details